Liver disease drugs
These companies develop drugs for fatty liver disease (MASH), cholestatic liver diseases and hepatitis B and delta.
+34.3%
over 1 year · S&P 500 +11.6%
Key indicators
Health
50 / 100
Fragile
Solid
Up over 1 year
4 of 10
Volatility
62%
Calm
Choppy
Profitability
−42%
Low
High
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 10 companies
GILD
+39.6%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
G
Gilead Sciences
GILD
91.4%
+39.6%
M
Madrigal Pharmaceuticals
MDGL
4.4%
−19.2%
M
Mirum Pharmaceuticals
MIRM
2.7%
+32.8%
V
Vir Biotechnology
VIR
0.8%
+74.4%
S
Sagimet Biosciences
SGMT
0.3%
+15.9%
A
Assembly Biosciences
ASMB
0.2%
−41.1%
A
Altimmune
ALT
0.1%
−61.1%
A
Aligos Therapeutics
ALGS
<0.1%
−67.5%
A
Arbutus Biopharma
ABUS
−15.5%
I
Inventiva
IVA
−9.1%